Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
McKinsey
Baxter
Johnson and Johnson
AstraZeneca

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

NASONEX Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Nasonex, and when can generic versions of Nasonex launch?

Nasonex is a drug marketed by Merck Sharp Dohme and is included in one NDA.

The generic ingredient in NASONEX is mometasone furoate. There are thirty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

Drug patent expirations by year for NASONEX
Drug Prices for NASONEX

See drug prices for NASONEX

Drug Sales Revenue Trends for NASONEX

See drug sales revenues for NASONEX

Recent Clinical Trials for NASONEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Washington University School of MedicinePhase 4
EMSPhase 3
Association Asthma, BulgariaPhase 4

See all NASONEX clinical trials

Recent Litigation for NASONEX

Identify potential future generic entrants

District Court Litigation
Case NameDate
MERCK SHARP & DOHME CORP. v. APOTEX INC.2015-04-02
Merck Sharp & Dohme Corp. v. Amneal Pharmaceuticals LLC2015-03-20
Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc.2014-07-03

See all NASONEX litigation

Pharmacology for NASONEX
Synonyms for NASONEX
(11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
(11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
(9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloranyl-17-(2-chloranylethanoyl)-10,13,16-trimethyl-11-oxidanyl-3-oxidanylidene-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
04201GDN4R
11?,16?)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate
2-furancarboxylic acid [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloro-1-oxoethyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] ester
83919-23-7
9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)
919M237
A840685
AB2000407
AC-941
AC1L9AZS
AK163902
AKOS015994732
AN-15438
Asmanex
Asmanex HFA
Asmanex Twisthaler
BC228151
BDBM50148733
BPBio1_000424
BRD-K60640630-001-03-7
BRD-K60640630-001-11-0
BRN 4340538
BSPBio_000384
C07817
C27H30Cl2O6
CAS-83919-23-7
CCG-220572
CHEBI:47564
CHEMBL1161
CS-2389
D00690
Danitin
DSSTox_CID_3333
DSSTox_GSID_23333
DSSTox_RID_76981
DTXSID4023333
Ecural
Elocone
Elomet
Flumeta
HMS1569D06
HMS2096D06
HMS2235I14
HMS3713D06
HY-13693
KS-00000SPL
KS-1275
LAS 41002
M2354
MLS002153879
MolPort-003-849-257
Mometasone 17-(2-furoate)
mometasone 17-furoate
mometasone furancarboxylate
mometasone furoate
Mometasone furoate (JAN/USP)
Mometasone furoate [USAN:USP:JAN]
Mometasone Furoate Impurity G
MOMETASONE FUROATE MONOHYDRATE
Mometasone furoate, >=98% (HPLC)
Mometasone furoate, European Pharmacopoeia (EP) Reference Standard
Mometasone Furoate, Pharmaceutical Secondary Standard; Certified Reference Material
Mometasone furoate, United States Pharmacopeia (USP) Reference Standard
Monovo
NCGC00016950-01
NCGC00179578-01
NCGC00179578-03
NCGC00179578-04
Nosorex
NSC-746171
NSC746171
Ovixan
Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)-
Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)-
Prestwick_924
Prestwick0_000572
Prestwick1_000572
Prestwick2_000572
Prestwick3_000572
Q-101380
Rimelon
s1987
Sch 32088
Sch-32088
SCHEMBL4568
Sinuva
SMR001233233
SPBio_002603
SR-01000841209
SR-01000841209-2
ST24048112
TL8005500
Tox21_110705
Tox21_110705_1
UNII-04201GDN4R
WOFMFGQZHJDGCX-ZULDAHANSA-N
ZINC3938677
Paragraph IV (Patent) Challenges for NASONEX
Tradename Dosage Ingredient NDA Submissiondate
NASONEX SPRAY, METERED;NASAL mometasone furoate 020762 2009-08-07

US Patents and Regulatory Information for NASONEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NASONEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997   Start Trial   Start Trial
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997   Start Trial   Start Trial
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997   Start Trial   Start Trial
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Moodys
Baxter
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.